copper cu 61 atsm

Drug Overview

Copper Cu 61 ATSM is a specialized investigational radioactive drug used in cancer imaging and treatment. It is not a traditional medicine that directly kills cancer cells in the way chemotherapy does. Instead, it works as both a diagnostic and therapeutic tool, depending on how it is used. This makes it a unique and exciting agent in the world of nuclear medicine and oncology.

This drug belongs to a class of agents known as radiopharmaceuticals. It uses a radioactive form of copper, called Copper-61, attached to a chemical molecule called ATSM (diacetyl-bis(N4-methylthiosemicarbazone)). Together, they form a smart compound that naturally seeks out oxygen-starved areas inside tumors.

Key Details:

• Generic Name: Copper Cu 61 ATSM (Copper (61Cu) diacetyl-bis(N4-methylthiosemicarbazone))
• US Brand Names: None currently. It remains an investigational compound with no commercially approved brand name.
• Drug Class: Radiopharmaceutical / Diagnostic and Therapeutic PET Imaging Agent / Hypoxia-Targeting Agent
• Route of Administration: Intravenous (IV) injection
• FDA Approval Status: Investigational. Not yet FDA-approved for standard clinical use. It is currently studied through approved clinical trials and holds investigational new drug (IND) status.

What Is It and How Does It Work? (Mechanism of Action)

Copper Cu 61 ATSM is specifically designed to find and target these hypoxic tumor regions. Here is how it works step by step at the molecular level:

Step 1 – Entering the Bloodstream and Traveling to the Tumor: After IV injection, the Copper Cu 61 ATSM compound travels freely through the bloodstream. Because the ATSM molecule is lipophilic (meaning it can pass easily through fatty cell membranes), it enters cells throughout the body without needing a special transporter.

Step 2 – The Oxygen-Sensitive Reaction (Selective Trapping): Inside a normal, healthy cell with adequate oxygen, the copper compound undergoes a chemical reaction. The Cu(II) form of copper gets briefly reduced to Cu(I). However, in the presence of normal oxygen levels, it gets quickly re-oxidized back to Cu(II) and washes back out of the cell. This means healthy, well-oxygenated cells do not retain the drug.

Inside a hypoxic (low-oxygen) tumor cell, the re-oxidation process cannot happen. The Cu(I) form remains trapped inside the cell permanently. The copper then dissociates from the ATSM molecule and binds to proteins inside the hypoxic cell, locking the radioactive copper inside.

Step 3 – Imaging with PET: Because Copper-61 is a positron-emitting isotope, it acts as a radioactive beacon. A PET scanner detects the signal from the trapped copper, creating a precise map of hypoxic regions inside the tumor. This tells the oncologist exactly where the most dangerous, treatment-resistant parts of the cancer are located.

Step 4 – Theranostic Potential: Copper Cu 61 ATSM is part of a broader theranostic strategy. This means the same ATSM molecule can be paired with other copper isotopes (such as Copper-64 for imaging or Copper-67 for therapy) to move from detecting hypoxic cells to directly destroying them. Copper Cu 61 specifically excels at high-resolution PET imaging due to its favorable half-life and low positron energy, which produces very sharp, detailed scan images.

FDA Approved Clinical Indications

Copper Cu 61 ATSM does not currently hold FDA approval for routine clinical use. It is actively investigated in clinical trials. The following indications reflect its current research applications:

Oncological Uses (In Clinical Trials):

• Glioblastoma (Brain Cancer): Used to map hypoxic regions in brain tumors to guide radiation therapy planning and predict treatment resistance.
• Head and Neck Cancers: Imaging hypoxic tumor zones to help radiation oncologists deliver higher doses precisely to the most resistant areas.
• Cervical Cancer: Studied as a predictor of treatment outcomes, as high hypoxia is associated with poorer prognosis.
• Prostate Cancer: Investigated for imaging hypoxic tumor cores that are likely to escape standard hormonal or radiation therapies.
• Lung Cancer (NSCLC): Used to identify high-risk, oxygen-deprived tumor regions and guide personalized treatment escalation.
• Colorectal Cancer: Under investigation as a predictive biomarker of chemotherapy and radiation resistance.

Non-Oncological Uses (In Clinical Trials):

• Cardiac Hypoxia Imaging: Investigated for detecting oxygen-deprived heart muscle tissue in patients with heart disease, though oncology remains the primary focus.
• Neurological Conditions: Early-stage research exploring its use in mapping hypoxic brain regions in stroke and neurodegenerative diseases.

Dosage and Administration Protocols

Copper Cu 61 ATSM is administered as a single IV injection immediately before a PET imaging session. Dosing is managed entirely by a licensed nuclear medicine physician.

Clinical Efficacy and Research Results

Research published between 2020 and 2025 continues to validate the clinical utility of Copper Cu 61 ATSM, particularly in hypoxia imaging for treatment planning and outcome prediction.

Imaging Quality and Precision: Studies comparing Copper Cu 61 ATSM to older hypoxia tracers, such as 18F-FMISO, consistently show that Copper Cu 61 ATSM produces superior image contrast and resolution. Its lower positron energy results in sharper PET images, allowing clinicians to define hypoxic tumor volumes with greater anatomical accuracy. This is particularly valuable for radiation therapy planning, where precise tumor mapping directly affects treatment success.

Predicting Treatment Resistance: Clinical research in head and neck cancers and glioblastoma has demonstrated that patients with high Copper Cu 61 ATSM uptake in their tumors are significantly more likely to have poor responses to standard radiation and chemotherapy. This predictive value allows oncologists to escalate treatment intensity or switch therapeutic strategies before wasting weeks or months on ineffective regimens.

Theranostic Pairing Studies: Ongoing multi-center trials are investigating the use of Copper Cu 61 ATSM as a companion diagnostic paired with Copper-67 ATSM therapy. Early results suggest that patients whose tumors retain the Cu-ATSM compound on diagnostic imaging are ideal candidates for Cu-67 ATSM-based targeted radiotherapy, potentially creating a fully personalized, image-guided treatment loop.

Cervical and Prostate Cancer Outcomes: Earlier foundational studies, supported by more recent follow-up data, indicate that high tumor uptake of Cu-ATSM in cervical cancer patients correlates with lower overall survival and disease-free survival rates compared to patients with low uptake. Similar trends have been observed in prostate cancer cohorts, reinforcing its role as a prognostic biomarker.

Safety Profile and Side Effects

Because Copper Cu 61 ATSM is administered in trace, sub-therapeutic amounts purely for imaging purposes, it does not produce the toxic side effects seen with traditional chemotherapy agents.

Black Box Warning: There is currently no FDA Black Box Warning associated with Copper Cu 61 ATSM, as it remains an investigational agent.

Common Side Effects (>10%):

• Injection Site Reactions: Mild redness, bruising, or discomfort at the IV insertion site.
• Mild Fatigue: Generalized tiredness related to the imaging procedure and clinic visit rather than the drug itself.

Serious Adverse Events (Rare):

• Hypersensitivity Reactions: As with any IV-administered agent, a rare risk of allergic reaction exists, including symptoms such as skin flushing, hives, or in very rare cases, anaphylaxis.
• Radiation Exposure: Though the radiation dose is low and comparable to standard diagnostic nuclear medicine procedures, cumulative radiation exposure should be tracked, especially for patients undergoing repeated imaging studies.

Management Strategies:

• For injection site bruising, apply a cool compress to the area.
• In the event of an allergic reaction, the medical team will immediately discontinue the infusion and administer appropriate emergency medications including antihistamines or epinephrine.
• To accelerate radiation clearance from the body, patients are encouraged to drink generous amounts of water and urinate frequently following the scan.

Research Areas

While Copper Cu 61 ATSM does not have a direct established role in stem cell or regenerative medicine at this time, its research trajectory is highly relevant to emerging combination therapies.

Immunotherapy Integration: Hypoxia is now understood to be a major suppressor of the immune system inside tumors. Hypoxic tumor microenvironments actively block immune cells, including T-cells, from entering and attacking cancer cells. Researchers are investigating whether Copper Cu 61 ATSM PET imaging can serve as a biomarker for predicting which patients will respond to immune checkpoint inhibitor therapies (such as anti-PD-1 or anti-CTLA-4 drugs). By identifying the most hypoxic, immune-suppressed zones, oncologists may be able to combine targeted hypoxia-busting strategies with immunotherapy to dramatically improve outcomes.

Radiation Sensitizer Trials: Additional research is exploring whether Cu-ATSM compounds, when combined with hypoxia-modifying agents or radiosensitizers, can convert resistant tumor zones into therapy-responsive ones, effectively reversing one of cancer’s most powerful defense mechanisms.

Patient Management and Practical Recommendations

Pre-Treatment Tests to Be Performed:

• Pregnancy Test: A negative serum pregnancy test is mandatory for all women of childbearing potential within one week before the procedure. Radioactive agents pose a risk to developing fetuses.
• Baseline Imaging: Prior CT or MRI scans are typically required to provide anatomical reference maps for correlation with the PET images.
• Renal Function Assessment: Basic kidney function labs may be ordered to confirm safe clearance of the radiotracer.

Precautions During Treatment:

• Patients must remain completely still during PET imaging, which typically lasts between 30 and 60 minutes, to prevent motion-related image blurring.
• A small amount of radiation will be present in your body for several hours after the scan. Avoid close, prolonged contact with pregnant women, nursing mothers, and young children for the remainder of the day.
• The procedure is performed in a certified nuclear medicine or radiology facility equipped with radiation safety infrastructure.

Do’s and Don’ts:

DO:

• Drink plenty of water before and after the scan to help flush the radiotracer through your kidneys efficiently.
• Empty your bladder frequently after the scan to reduce pelvic radiation exposure.
• Follow all fasting or dietary instructions provided by your nuclear medicine team before the scan.
• Inform your care team about all medications, supplements, and any history of allergic reactions before the procedure.

DON’T:

• Do not bring pregnant family members, nursing mothers, or infants to your imaging appointment.
• Do not engage in strenuous physical exercise for at least 24 hours before the scan, as muscle activity can alter tracer distribution patterns.
• Do not breastfeed for a recommended period after the scan; consult your nuclear medicine physician for the exact duration based on your specific dose.

Legal Disclaimer

The information provided in this guide is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Copper Cu 61 ATSM is an investigational radiopharmaceutical agent and is not currently approved by the United States Food and Drug Administration (FDA) for routine clinical use. Access to this agent is available exclusively through participation in approved clinical trials under the supervision of qualified medical professionals. Individual patient eligibility, dosing, and treatment decisions must be made by a licensed oncologist or nuclear medicine physician based on a thorough clinical evaluation. Always consult your healthcare provider before making any decisions regarding your medical care.